Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Diet Composition, Weight Control, and Breast Carcinogenesis (CHOICE)

13 de febrero de 2013 actualizado por: Henry J. Thompson, Colorado State University

In the United States, overweight (BMI > 25 but < 30 Kg/m2) and obesity (BMI > 30Kg/m2) are increasing at epidemic rates. A significant association exists between being overweight or obese and breast cancer recurrence and survival. However, evidence continues to accumulate indicating that achieving or maintaining a healthy weight for height (Body Mass Index, BMI, 18.5-25Kg/m2) is associated with a reduced risk for breast cancer and with a decrease in breast cancer associated mortality. Despite this, there is a lack of randomized controlled trials exploring this association and how the process of fat loss or being successful in actually reaching a healthy weight for height differentially affects biomarkers for cancer recurrence.

Many dietary approaches for weight loss are currently available to the public, and each purports to offer advantages. However, there is little scientific evidence to indicate how these dietary approaches, some of which vary markedly in the foods that they limit or exclude, affect biomarkers for breast cancer risk. In particular, it is not know whether the critical factor in relation to weight and breast cancer is simply weight loss (negative energy balance), irrespective of the manner in which it is achieved, or if certain dietary approaches affect breast cancer risk biomarkers more favorably than others. Published data from our laboratory suggest that dietary pattern does matter, and therefore the goal of this study is to investigate the effects of two popular weight loss dietary approaches that differ in the extent to which they limit carbohydrate or fat consumption (with effects on dietary glycemic load) compared to a usual care group on prognostic markers for cancer recurrence in postmenopausal breast cancer survivors. The investigators hypothesize that in addition to the anticipated effects of fat loss on circulating levels of bioavailable sex steroid hormones, that the effects of excess fat on breast cancer prognosis can be attributed to three interrelated metabolic processes that affect cancer progression: altered glucose metabolism, chronic inflammation and excessive cellular oxidation.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

This study is designed to answer questions about how a dietary pattern either high or low in dietary carbohydrate and fat availability and fat loss influence metabolic and hormonal processes that may affect breast cancer recurrence. The investigators hypothesize that in addition to the anticipated effects of fat loss on circulating levels of bioavailable sex steroids, that the effects of excess fat on breast cancer prognosis can be attributed to three interrelated metabolic processes: altered glucose metabolism (IGF-1, IGFBP-3, glycated proteins), chronic inflammation (C-reactive protein, IL-6, TNF-alpha) and excessive cellular oxidation (8-hydroxy-2-deoxyguanosine and 8-isoprostane F-2 alpha).

A 6 month intervention study involving 370 post menopausal women who have been treated for breast cancer is proposed. Randomized women, stratified by resected stage, systemic adjuvant therapy and body mass index (> 25 and < 35 Kg/m2), will serve as either a non-intervention control group or will follow a tailored diet-physical activity program designed to create a weekly negative energy balance equivalent to 3500 kcal. The intervention groups will receive the same physical activity protocol, but one of two diets that differ in dietary pattern.

The specific aims are: Aim 1. Does a dietary pattern either high or low in available carbohydrate and fat alter the pattern of change observed in circulating factors involved in glucose homeostasis, chronic inflammation, cellular oxidation, and steroid hormone metabolism during progressive loss of body fat? The investigators will also examine how observed changes in these circulating factors related to changes indicators of breast cancer recurrence. Aim 2. Do circulating factors associated with glucose homeostasis, chronic inflammation, and cellular oxidation display the same pattern of change in response to progressive fat loss as circulating analytes associated with sex steroid metabolism? Analytes of interest will be measured monthly throughout the study. Aim 3. Does dietary glycemic load affect the magnitude or rate of fat loss? Plasma adipokines such as leptin and adiponectin and plasma ghrelin will be measured to provide biological determinants that may help explain differences in response.

The work proposed in this application should provide quantitative data about the importance of the magnitude of fat loss on metabolic and hormonal processes involved in cancer recurrence and provide guidance about effective dietary approaches that maximize weight loss benefits on breast cancer prognosis.

Tipo de estudio

Intervencionista

Inscripción (Actual)

259

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Colorado
      • Denver, Colorado, Estados Unidos, 80220
        • Rocky Mountain Cancer Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Female breast cancer survivors
  • Staged, resected breast cancer (> 4-months post radiation treatment, chemotherapy or surgery)
  • Post-menopausal (no menses for > 6 months)
  • No evidence of metastatic breast disease
  • Willing to follow the diet plan prescribed
  • Willing to follow the guidelines for alcohol consumption (no more than 1 standard alcoholic drink per day where one serving is defined as 12oz beer, 5 oz wine OR 1 oz hard liquor)
  • Willing to maintain or increase current physical activity level
  • Willing to wear a pedometer and keep a daily record of steps
  • Willing to wear heart rate/ accelerometer device (Actiheart) continuously (24/7) for one week at the start and end of the study
  • Willing to wear a body or swim suit and cap for body composition tests
  • Willing to record food intake daily
  • Willing to come to RMCC Rose for 11 individual and 5 group sessions over a 6 month period
  • Willing to provide urine and fasting blood samples at 7 visits during the study
  • Willing to make the commitment it takes to lose weight for the study
  • Must have a Body Mass Index between 25Kg/m2 to 35Kg/m2.

Exclusion Criteria:

  • Anticipates having surgery during the next 6 months
  • Follows a special diet, e.g. gluten free, casein free, dairy free, vegetarian or other
  • Lost 4 or more pounds during the previous month
  • Taking weight loss medications during the study
  • Being treated by a physician for diabetes
  • Has an eating disorder
  • Has digestive problems such as IBS (Irritable Bowel Syndrome), Crohn's or other
  • Has had surgery involving constriction or removal of any portion of the gastrointestinal tract (gastric bypass, lap-band, bowel resection, colostomy etc.
  • Diagnosed with hepatitis B, hepatitis C or HIV
  • Has electronic devices implanted in their body (pacemaker, vagus nerve stimulator)
  • Must not use any tobacco products

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Control
Cuidado usual
Experimental: Low fat, high carb weight loss diet
Ornish-like weight loss dietary pattern
Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
Otros nombres:
  • Low fat, high carb weight loss diet (Vivace Diet)
  • Low carb, high fat weight loss diet (Ricca Diet)
Experimental: Low carb, high fat weight loss diet
South-Beach-like weight loss diet pattern
Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
Otros nombres:
  • Low fat, high carb weight loss diet (Vivace Diet)
  • Low carb, high fat weight loss diet (Ricca Diet)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Inflammation Markers
Periodo de tiempo: Baseline and montlhly for 6 months
C-reactive protein, IL-6, TNF-alpha
Baseline and montlhly for 6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Body Fat Percentage (%)
Periodo de tiempo: Baseline and monthly for 6 months
% Body fat, % lean muscle mass, Resting Metabolic Rate (RMR) using the BODPOD (Volumetric weighing; Life Measurement, Inc.) and Tanita Bioelectrical Impedence (BI)
Baseline and monthly for 6 months
Waist Hip Ratio
Periodo de tiempo: Baseline and monthly for 6 months
Calculated by measuring and dividing waist and hip circumferences
Baseline and monthly for 6 months
Weight
Periodo de tiempo: Baseline and monthly for 6 months
Using 1) BODPOD (Life Measurement, Inc.) and 2) Tanita Bioelectrical Impedence Scale
Baseline and monthly for 6 months
Bioavailable sex steroid hormones
Periodo de tiempo: Baseline and monthly for 6 months
estradiol, estrone, sex hormone binding globulin (SHBG)
Baseline and monthly for 6 months
Glucose metabolism
Periodo de tiempo: Baseline and monthly for 6 months
glucose, insulin, IGF-1, IGFBP-3, glycated proteins (HbA1c)
Baseline and monthly for 6 months
Cellular oxidation
Periodo de tiempo: Baseline and monthly for 6 months
8-hydroxy-2-deoxyguanosine, DNA damage sensitivity and repair and 8-isoprostane-F-2-alpha
Baseline and monthly for 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Henry J Thompson, PhD, Colorado State University
  • Investigador principal: Scot M Sedlacek, MD, Rocky Mountain Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de septiembre de 2008

Finalización primaria (Actual)

1 de enero de 2012

Finalización del estudio (Actual)

1 de junio de 2012

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2011

Primero enviado que cumplió con los criterios de control de calidad

14 de marzo de 2011

Publicado por primera vez (Estimar)

15 de marzo de 2011

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

15 de febrero de 2013

Última actualización enviada que cumplió con los criterios de control de calidad

13 de febrero de 2013

Última verificación

1 de febrero de 2013

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CA125243

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir